Skip to main content

Engaging Patients in Decision Helps Reduce Antibiotic Use


July 30, 2012 — Training physicians to engage patients in decision-making can reduce the prescription of unnecessary antibiotics for acute respiratory infections, according to a randomized trial of 359 patients published in the Canadian Medical Association Journal.
In the cluster randomized trial, the use of antibiotics for acute respiratory infection was reduced by 25% among patients of Canadian physicians from 5 family practices who were trained in physician–patient shared decision-making compared with use among patients of physicians who provided "usual care" (27.2% vs 52.2%; adjusted relative risk, 0.48; 95% confidence interval, 0.34 - 0.68).
The reduction in antibiotic use had no significant effect on patient outcomes from respiratory infection 2 weeks after patients consulted with their physicians about symptoms of acute respiratory infection, according to lead author France Légaré, MD, PhD, from the Research Centre of the Centre Hospitalier Universitaire de Québec and the Department of Family Medicine and Emergency Medicine, Université Laval, Québec, Canada, and colleagues.
"Our data suggest that it is possible to train physicians to engage patients actively in decision-making. In the context of acute respiratory infections, this appears to reduce the use of a treatment option (i.e., antibiotics) not clearly associated with benefits for all patients," the authors write.
In the multicenter, parallel cluster randomized trial, the researchers compared use of antibiotics for acute respiratory infection among patients of 77 physicians who participated in the physician–patient shared decision-making training program with prescriptions for antibiotics among 72 physicians who provided usual care.
As well as reducing use of antibiotics for acute respiratory infections, patients of physicians who took the training program took a more active role in decision-making about their treatment compared with patients of physicians in the control group (P < .001). Active patient decision-making was assessed by a questionnaire after the physician–patient consultation and the Control Preference Scale, which assessed patient perceptions that shared decision-making had occurred.
The shared decision-making training program, known as DECISION+2, consisted of a 2-hour online tutorial followed by a 2-hour interactive seminar on shared physician–patient decision-making. The program included information about the scientific evidence for use of antibiotics in acute respiratory infection as well as training in communication with patients about the risks and benefits of antibiotic use.
In the training program, physicians were also educated about ways to promote active patient participation in the decision of whether or not to use antibiotics. These techniques included asking patients about their preferences and values and verifying patient comfort with the final decision about use of antibiotics.
The authors noted that training programs in shared patient–clinician decision-making might be useful in other settings such as emergency departments or to train nurses to help patients make informed decisions based on their values before visiting a physician or emergency department.
The study was funded by a grant from the Conseil du médicament du Québec/Fonds de la recherche en santé du Québec. The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more